No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 11 of the 30 quarters in the window, leaving 19 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 16.1x · 10Y median 34.9x · 17th percentile · as of Oct 2, 2026
Annualized revenue (TTM) · by quarter, last 31
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-02T19:40:13.826Z. Latest historical point 2026-10-01. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-02T19:40:13.826Z. Latest historical point 2023-05-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-02T19:40:13.826Z. Latest historical point 2023-02-28. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-02T19:40:13.826Z. Latest historical point 2023-05-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-02T19:40:13.826Z. Latest historical point 2023-02-28. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Beam Therapeutics Inc. (BEAM) stock was $24.38 as of Oct 2, 2026, 3:40 PM EDT, down 0.03% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +1.1% · 3-year avg +0.5%/yr · 5-year avg -22.4%/yr
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States.
Biotechnology · Cambridge, MA
Next Earnings Date
Nov 3, 2026
32 days away
EPS Estimate
-1.16
Revenue Est.
$8.75M
Last Quarter Results
EPS
$-1.18
vs Estimate
$-1.13
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1BEAM | $2.51B | $24.38 | -0.03% | +1.08% | -22.35% | N/A | N/A |
| 2TMDX | $2.74B | $79.27 | +0.80% | -31.57% | +19.20% | N/A | vs BEAM |
| 3RXRX | $2.14B | $4.08 | +0.37% | -20.21% | -28.56% | N/A | vs BEAM |
| 4XRAY | $1.73B | $8.62 | -1.43% | -31.59% | -30.33% | -16.27% | vs BEAM |
| 5NTLA | $1.71B | $12.24 | +1.03% | -35.41% | -38.17% | -3.34% | vs BEAM |
| 6TDOC | $997.45M | $5.49 | -3.17% | -27.32% | -46.28% | -11.06% | vs BEAM |
forward FY estimate
N/A
$490000.00
vs Estimate
$16.37M
Consensus Rating
Based on 13 analysts
Average Price Target
$52.15
+113.9% upside
Low
$26.00
Current
$24.38
High
$80.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.25 | $-1.15 | $-0.99 | 9 |
| Quarter ending Dec 2026 | $-1.25 | $-1.18 | $-1.12 | 8 |
| Quarter ending Mar 2027 | $-4.10 | $-1.22 | $0.30 | 3 |
| Quarter ending Jun 2027 | $-4.20 | $-1.24 | $0.30 | 4 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-4.61 | $-4.43 | $-4.22 | 11 |
| FY 2027 | $-5.42 | $-4.79 | $-3.90 | 9 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $387705.00 | $8.75M | $25.08M | 7 |
| Quarter ending Dec 2026 | $448909.00 | $10.13M | $29.04M | 7 |
| Quarter ending Mar 2027 | $623187.00 | $14.25M | $40.24M | 3 |
| Quarter ending Jun 2027 | $623187.00 | $14.25M | $40.24M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $31.30M | $51.24M | $90.18M | 10 |
| FY 2027 | $2.73M | $63.83M | $183.46M | 9 |
